Chicago, IL—Advances in the understanding of the biology of multiple myeloma (MM) and the identification of new drugs have resulted in improved management of MM, including for patients who are refractory to proteasome inhibitors and immunomodulatory agents.
At the 2013 American Society of Clinical Oncology annual meeting, Donna E. Reece, MD, Site Group Medical Lead, Myeloma Clinic, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, discussed updated approaches to initial therapy.
Chicago, IL—The updated survival analysis of the phase 3 MM-03 trial of pomalidomide (Pomalyst) plus low-dose dexamethasone upheld the progression-free survival (PFS) and overall survival (OS) benefit of this regimen in patients with relapsed or refractory multiple myeloma, study investigators reported at the 2013 American Society of Clinical Oncology annual meeting.
Chicago, IL—The final results of the phase 1 study of the oral investigational proteasome inhibitor MLN9708 (ixazomib), given as a single agent to patients with relapsed and/or refractory multiple myeloma (RRMM), were reported by Shaji K. Kumar, MD, Professor of Medicine at the Mayo Clinic, Rochester, MN, at the 2013 American Society of Clinical Oncology annual meeting.
Results 1 - 4 of 4